FuRST 2.0 for Huntington’s: early daily changes, made measurable
Interactive explainer and quick market context on QURE from your supplied text.
FuRST 2.0 is a patient‑reported outcome measure built to detect early, subtle functional changes in Huntington’s disease (HD). Details in the column “New HD research puts patients ‘FuRST’”. Related background: AMT‑130 gene therapy and CAG repeats staging context.

Simulate a subtle daily change
Adjust the slider to represent small changes noticed at home (e.g., phone calls, driving, last‑minute plan changes). Select the stage.
FuRST 2.0 targets early functional change in Stage 2 and mild Stage 3.
What’s in the provided text
The CHDI Clinical Outcomes group developed FuRST 2.0 using focus groups, expert panels, and cognitive interviews across six countries. The FOCUS‑HD Online component is anonymous (~20 minutes).
Study contact: FOCUSOnlineStudy@chdifoundation.org. Related reads on Karmactive: cell transplant (mice), cellular memory, patient personas.
uniQure (QURE): context from the attached text
- Stock noted up 6.09% on Oct 9, 2025 following clinical news on AMT‑130.
- Analyst target increases mentioned: Wells Fargo, Guggenheim, H.C. Wainwright, and Cantor Fitzgerald.
- Recent figures referenced: revenue $27.12M; operating income −$43.87M.
- Liquidity referenced: current ratio ~10; quick ratio ~6.2.
This card repeats the supplied text and is not investment advice.